Just In
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.

Biosimilar

(3 search results)

Biocon Biologics gets US FDA nod for Jobevne, a biosimilar for cancer treatment
Biocon developing 20 biosimilar products for global markets
Biocon wins US patent battle against Sanofi on insulin biosimilar